Search Result

Results for "

rap1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (2) ADC Antibody (2) Akt (2) AMPK (6) Apoptosis (8) Autophagy (6) Biochemical Assay Reagents (1) Farnesyl Transferase (2) GGTase (2) Heme Oxygenase (HO) (2) IFNAR (1) Integrin (2) Isotope-Labeled Compounds (2) JNK (1) Keap1-Nrf2 (2) MEK (1) Mitophagy (6) mTOR (8) NF-κB (2) p38 MAPK (1) PDGFR (1) Phosphatase (1) PI3K (2) PKA (1) Protein Prenyltransferase (2) Ras (11) Reference Standards (4) Small Interfering RNA (siRNA) (13) STAT (2) TGF-beta/Smad (2) TNF Receptor (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (13) Infection (4) Inflammation/Immunology (7) Metabolic Disease (10) Neurological Disease (5)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (3) Human Pre-designed siRNA Sets (8) siRNAs (13)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0627

Metformin Maximum Cited Publications 196 Publications Verification 1,1-Dimethylbiguanide	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-17471A

Metformin hydrochloride Maximum Cited Publications 196 Publications Verification 1,1-Dimethylbiguanide hydrochloride	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-15871

GGTI298 Trifluoroacetate 5+ Cited Publications	Apoptosis	Cancer
GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit *Rap1A* with IC₅₀ of 3 μM; little effect on Ha-Ras with IC₅₀ of >20 μM.

HY-107543

8-pCPT-2′-O-Me-cAMP sodium 1 Publications Verification 8-CPT-2'-O-Me-cAMP sodium	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a *Rap1* activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration ^[1] .

HY-N0657

Pinoresinol Diglucoside 1 Publications Verification	NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, *HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads*. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis ^[1] .

HY-17471AR

Metformin hydrochloride (Standard) 1,1-Dimethylbiguanide hydrochloride (Standard)	Reference Standards AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin hydrochloride (Standard) is the analytical standard of Metformin hydrochloride (HY-17471A). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-117958

HJC0197 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
HJC0197 is a potent *Epac1* (exchange protein directly activated by cAMP 1) and Epac2 (IC₅₀=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP ^[1].

HY-100876

GGTI298	Apoptosis	Cancer
GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC₅₀ values of 3 and > 20 μM in vivo, respectively.

HY-123242

FTI-2153	Farnesyl Transferase	Cancer
FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity ^[1].

HY-126133

AM-001	Ras	Cardiovascular Disease Others
AM-001 is a non-competitive inhibitor of *Epac1* that blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells. AM-001 can be used in heart disease-related research ^[1].

HY-B0627S

Metformin-d6 1,1-Dimethylbiguanide-d₆	Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Cancer
Metformin-d₆ (1,1-Dimethylbiguanide-d₆) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates *Epac-Rap* signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway ^[1] .

HY-132276

PtdIns-(3,4,5)-P3-biotin sodium	Phosphatase	Others
PtdIns-(3,4,5)-P3-biotin sodium is a Biotin-labeled PtdIns-(3,4,5)-P3 (PI(3,4,5)P3). PI(3,4,5)P3 is a substrate of nuclear phosphatidylinositol 5-phosphatase (PIP5Pase). PI(3,4,5)P3 binds to the N-terminus of *RAP1* (repressor activator protein 1) and controls its DNA binding activity ^[1].

HY-12369

GGTI-2133 1 Publications Verification	GGTase	Inflammation/Immunology
GGTI-2133, a peptidomimetic, is a selective geranylgeranyltransferase I (GGTase-I) inhibitor with an IC₅₀ of 38 nM. GGTI-2133 shows 140-fold selectivity over farnesyltransferase (FTase) (IC₅₀ of 5.4 μM). GGTI-2133 inhibits the geranylation of Rap-1A with an IC₅₀ of 10 μM. GGTI-2133 can be used for the study of eosinophilic airway inflammation such as asthma ^[1] .

HY-P10038A

mP6 TFA Myr-FEEERA-OH TFA	Integrin	Infection
mP6 (Myr-FEEERA-OH) TFA is a myristoylated peptide. mP6 TFA inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 TFA can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells ^[1].

HY-115489

GGTI-286	Ras	Cancer
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM ^[1] .

HY-115489A

GGTI-286 TFA	Protein Prenyltransferase	Cancer
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM ^[1] .

HY-116312

8-pCPT-2′-O-Me-cAMP 8-CPT-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a *Rap1* activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration ^[1] .

HY-169295

*RAP 1*	Biochemical Assay Reagents	Others
RAP 1 is a reactive affinity probe (RAP) that selectively labels SLC6A8 in the presence of guanine alanine (GPA). RAP 1 can be used as a chemical probe for identifying and studying potential drug binding sites on SLC6A8 ^[1].

HY-12369A

GGTI-2133 TFA	GGTase	Inflammation/Immunology
GGTI-2133 TFA, a peptidomimetic, is a selective geranylgeranyltransferase I (GGTase-I) inhibitor with an IC₅₀ of 38 nM. GGTI-2133 TFA shows 140-fold selectivity over farnesyltransferase (FTase) (IC₅₀ of 5.4 μM). GGTI-2133 TFA inhibits the geranylation of Rap-1A with an IC₅₀ of 10 μM. GGTI-2133 TFA can be used for the study of eosinophilic airway inflammation such as asthma ^[1] .

HY-B0627A

Metformin (glycinate) 1,1-Dimethylbiguanide (glycinate)	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin (1,1-Dimethylbiguanide) glycinate inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin glycinate exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin glycinate also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin glycinate regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-B0627S1

Metformin-13C2 hydrochloride 1,1-Dimethylbiguanide-13C2 hydrochloride	Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin- ¹³C₂ (1,1-Dimethylbiguanide- ¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-RS16300

Rap1a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Cancer
Rap1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rap1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rap1a Mouse Pre-designed siRNA Set A Rap1a Mouse Pre-designed siRNA Set A

HY-RS11652

RAP1A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAP1A Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAP1A Human Pre-designed siRNA Set A RAP1A Human Pre-designed siRNA Set A

HY-186198

FTS-MOM Salirasib methoxymethyl ester	Ras	Others
FTS-MOM (Salirasib methoxymethyl ester), a Salirasib (FTS) (HY-14754) derivative, is a selective *Rap1* inhibitor with selectivity over Ras. FTS-MOM inhibits GTP loading of Rap1 in quiescent and activated T cells. FTS-MOM inhibits Rap1-dependent T cell adhesion to ICAM-1 ^[1].

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells ^[1].

HY-123242A

FTI-2153 TFA	Farnesyl Transferase	Cancer
FTI-2153 TFA is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 TFA is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity ^[1].

HY-120271

GGTI-297	Ras	Cancer
GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC₅₀ values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras ^[1] .

HY-RS11654

RAP1GAP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAP1GAP Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAP1GAP Human Pre-designed siRNA Set A RAP1GAP Human Pre-designed siRNA Set A

HY-RS16301

Rap1b Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Cancer
Rap1b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rap1b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rap1b Mouse Pre-designed siRNA Set A Rap1b Mouse Pre-designed siRNA Set A

HY-RS11653

RAP1B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAP1B Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAP1B Human Pre-designed siRNA Set A RAP1B Human Pre-designed siRNA Set A

HY-RS11655

RAP1GAP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAP1GAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAP1GAP2 Human Pre-designed siRNA Set A RAP1GAP2 Human Pre-designed siRNA Set A

HY-RS11656

RAP1GDS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAP1GDS1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GDS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAP1GDS1 Human Pre-designed siRNA Set A RAP1GDS1 Human Pre-designed siRNA Set A

HY-RS02389

CDK5RAP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5RAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5RAP1 Human Pre-designed siRNA Set A CDK5RAP1 Human Pre-designed siRNA Set A

HY-N0657R

Pinoresinol Diglucoside (Standard)	Reference Standards NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Pinoresinol Diglucoside (Standard) is the analytical standard of Pinoresinol Diglucoside (HY-N0657). This product is intended for research and analytical applications. Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.

HY-RS14374

TERF2IP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TERF2IP Human Pre-designed siRNA Set A contains three designed siRNAs for TERF2IP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TERF2IP Human Pre-designed siRNA Set A TERF2IP Human Pre-designed siRNA Set A

HY-RS11586

RABGEF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RABGEF1 Human Pre-designed siRNA Set A contains three designed siRNAs for RABGEF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RABGEF1 Human Pre-designed siRNA Set A RABGEF1 Human Pre-designed siRNA Set A

HY-182273

DM243	STAT Acyltransferase	Others
DM243 is an *EPAC1* activator and STAT3 modulator with an pIC₅₀ of 4.769 for EPAC1. DM243 increases GTP-bound *Rap1* levels in *EPAC1*-expressing cells. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses *TGF-β1*-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts ^[1].

HY-120229

GGTI-2147	Protein Prenyltransferase	Neurological Disease
GGTI-2147 is a potent GGTase I inhibitor. GGTI-2147 blocks geranyl-geranylation of Rap1A and reduces the activity of Rac1 (one of substrates for GGTI) and ameliorates the OGD/R-induced neuronal apoptosis.GGTI-2147 can be used for neurodevelopmental disorders research, such as autism, depression, and schizophrenia ^[1].

HY-182274

DM245	Acyltransferase STAT	Others
DM245 is an *EPAC1* activator and STAT3 phosphorylation inhibitor with a target pIC₅₀ of 4.801. DM245 activates *EPAC1* to increase Rap1-GTP levels, with no activation of EPAC2 or PKA. DM245 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM245 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing αSMA and Collagen I levels. DM245 exhibits minimal cytotoxicity in normal human lung fibroblasts, with negligible loss of intact nuclei after 72 h exposure ^[1].

HY-117935

GGTI-286 hydrochloride	Ras	Cancer
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM ^[1] .

HY-107091R

Aspartyl-alanyl-diketopiperazine (Standard) DA-DKP (Standard)	Reference Standards MEK p38 MAPK IFNAR TNF Receptor Ras JNK	Inflammation/Immunology
Aspartyl-alanyl-diketopiperazine (DA-DKP) (Standard) is the analytical standard of Aspartyl-alanyl-diketopiperazine (HY-107091). This product is intended for research and analytical applications. Aspartyl-alanyl-diketopiperazine is an immunomodulatory molecule and anti-inflammatory agent. Aspartyl-alanyl-diketopiperazine increases the level of active *Rap1* in activated human T lymphocytes and reduces the phosphorylation levels of Ras, ATF-2, c-jun, *MEK1, MEKK1, ERK1, JNK1,2,3, p38MAPK* and MEF-2. Aspartyl-alanyl-diketopiperazine inhibits the production of pro-inflammatory cytokines, including the levels of IFN-γ and TNF-α. Aspartyl-alanyl-diketopiperazine can be used in studies of inflammatory immune responses ^[1] .

HY-RS29280

Rap1b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rap1b Rat Pre-designed siRNA Set A contains three designed siRNAs for Rap1b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rap1b Rat Pre-designed siRNA Set A Rap1b Rat Pre-designed siRNA Set A

HY-RS22068

Rap1gap2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rap1gap2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rap1gap2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rap1gap2 Mouse Pre-designed siRNA Set A Rap1gap2 Mouse Pre-designed siRNA Set A

HY-RS28586

Rap1gap2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rap1gap2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rap1gap2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rap1gap2 Rat Pre-designed siRNA Set A Rap1gap2 Rat Pre-designed siRNA Set A

HY-107543R

8-pCPT-2′-O-Me-cAMP sodium (Standard) 8-CPT-2'-O-Me-cAMP sodium (Standard)	Reference Standards Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP sodium (Standard) is the analytical standard of 8-pCPT-2′-O-Me-cAMP (sodium) (HY-107543). This product is intended for research and analytical applications. 8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration ^[1] .

HY-180801

E8431	PDGFR Ras	Metabolic Disease
E8431 is a DCSTAMP antagonist. DCSTAMP is a key fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits the cytoskeleton reorganization mediated by the *RAP1B-RAC1* signaling pathway. E8431 has the ability to inhibit pre-fusion of osteoclasts and, while inhibiting bone resorption, stimulates the secretion of PDGFBB, thereby stimulating the process of bone and blood vessel formation. E8431 effectively reduces bone loss in a mouse model caused by ovariectomy. E8431 can be used for the study of osteoporosis ^[1].

HY-P992027

CSC012 Antibidy	ADC Antibody	Cancer
CSC012 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. CSC012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) CSC012. ADV-101 Antibody can be used to research related to acute myeloid leukemia ^[1].

HY-P992026

ADV-101 Antibody	ADC Antibody	Cancer
ADV-101 Antibody is a monoclonal antibody inhibitor targeting *IL-1RAP*. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P10038A

mP6 TFA Myr-FEEERA-OH TFA	Integrin	Infection
mP6 (Myr-FEEERA-OH) TFA is a myristoylated peptide. mP6 TFA inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 TFA can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells ^[1].

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells ^[1].

Cat. No.	Product Name	Target	Research Area	Image

HY-P992027

CSC012 Antibidy	ADC Antibody	Cancer
CSC012 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. CSC012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) CSC012. ADV-101 Antibody can be used to research related to acute myeloid leukemia ^[1].

HY-P992026

ADV-101 Antibody	ADC Antibody	Cancer
ADV-101 Antibody is a monoclonal antibody inhibitor targeting *IL-1RAP*. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0657

Pinoresinol Diglucoside 1 Publications Verification	Structural Classification Eucommia ulmoides Oliver Classification of Application Fields Lignans Other Diseases Eucommiaceae Phenylpropanoids Plants Disease Research Fields Source Classification	NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K
Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, *HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads*. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis ^[1] .

HY-N0657R

Pinoresinol Diglucoside (Standard)	Structural Classification Eucommia ulmoides Oliver Lignans Eucommiaceae Phenylpropanoids Plants Source Classification	Reference Standards NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K
Pinoresinol Diglucoside (Standard) is the analytical standard of Pinoresinol Diglucoside (HY-N0657). This product is intended for research and analytical applications. Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.

Cat. No.	Product Name	Chemical Structure

HY-B0627S

Metformin-d6

Metformin-d₆ (1,1-Dimethylbiguanide-d₆) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

HY-B0627S1

Metformin-13C2 hydrochloride

Metformin- ¹³C₂ (1,1-Dimethylbiguanide- ¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo ^[1] .

Host:	Mouse (2) Rabbit (6)
Reactivity:	Human (8) Rat (6) Mouse (7)
Application:	IHC-P (5) ICC/IF (3) IP (4) IHC-F (3) WB (8) FC (3)
Isotype:	IgG (6) IgG2a (2)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (5) Recombinant (4)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82081

	RAP1GAP Antibody (YA1826) rap1GAP; KIAA0474; rap1GA1; rap1 GTPase-activating protein 1; rap1GAP; rap1GAP1	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	RAP1GAP Antibody (YA1826) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RAP1GAP.

HY-P82081A

	RAP1GAP Antibody (YA1826)(PBS only) rap1GAP; KIAA0474; rap1GA1; rap1 GTPase-activating protein 1; rap1GAP; rap1GAP1	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	RAP1GAP Antibody (YA1826) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RAP1GAP.

HY-P87048

	RAP1A + RAP1B Antibody (YA6741) C21KG antibody; G 22K antibody; G-22K antibody; GTP binding protein smg p21A antibody; GTP-binding protein smg p21A antibody; KREV 1 antibody; KREV1 antibody; OTTHUMP00000013741 antibody; rap 1A antibody; rap1 antibody; C21KG antibody; G 22K antibody; G-22K antibody; GTP binding protein smg p21A antibody; GTP-binding protein smg p21A antibody; KREV 1 antibody; KREV1 antibody; OTTHUMP00000013741 antibody; rap 1A antibody; rap1 antibody; rap1A antibody; rap1A member of RAS oncogene family antibody; rap1A_HUMAN antibody; Ras related protein Krev 1 antibody; Ras related protein rap 1A antibody; RAS related protein rap1A antibody; Ras-related protein Krev-1 antibody; Ras-related protein rap-1A antibody; SMGP21 antibody; GTP-binding protein smg p21B antibody; K-REV antibody; OK/SW-cl.11 antibody; RAL1B antibody; rap1b antibody; rap1B member of RAS oncogene family antibody; rap1B_HUMAN antibody; Ras family small GTP binding protein rap1B antibody; RAS related protein rap1B antibody; Ras-related protein rap-1b antibody; Small GTP binding protein antibody;	WB, FC	Human, Mouse
	RAP1A + RAP1B Antibody (YA6741) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RAP1A + RAP1B.

HY-P82079

	RAP1A+RAP1B Antibody (YA1824) Ras-related protein rap-1b; K-REV; RAL1B	WB, IP, FC	Human, Mouse, Rat
	RAP1A+RAP1B Antibody (YA1824) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RAP1A+RAP1B.

HY-P82079A

	RAP1A+RAP1B Antibody (YA1824)(PBS only) Ras-related protein rap-1b; K-REV; RAL1B	WB, IP, FC	Human, Mouse, Rat
	RAP1A+RAP1B Antibody (YA1824) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RAP1A+RAP1B.

HY-P88124

	USP48 Antibody (YA7808) rap1GA1; USP31	WB, IHC-P	Human, Mouse, Rat
	USP48 Antibody (YA7808) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to USP48.

HY-P88124A

	USP48 Antibody (YA7808)(PBS only) rap1GA1; USP31	WB, IHC-P	Human, Mouse, Rat
	USP48 Antibody (YA7808) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to USP48.

HY-P82893

	D4 GDI Antibody (YA2638) Rho GDP dissociation inhibitor (GDI) beta; D4; GDIA2; GDID4; LYGDI; Ly-GDI; rap1GN1; RhoGDI2	WB, IHC-F, IHC-P, ICC/IF	Human
	D4 GDI Antibody (YA2638) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to D4 GDI.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks